论文部分内容阅读
目的:系统评价紫杉醇剂量密集化疗在原发性上皮性卵巢癌中的疗效与安全性.方法:检索Cochrane Library、Pubmed、Embase、Medline、中国知网(CNKI)、维普(VIP)、万方、中国生物医学文献数据库( CBM)等数据库,并手工检索会议摘要及相关参考文献,应用Cochrane偏倚风险评估工具5. 1版进行偏倚风险评价,RevMan 5. 3行Meta分析.结果:纳入11项RCT研究共4 590例患者,Meta分析结果显示紫杉醇剂量密集化疗与三周化疗方案无进展生存期(progressio free survival,PFS)(HR=0. 89,95% CI 0. 77 ~1. 04,P=0. 14)、整体生存率(overall survival,OS) ( HR=0. 94,95% CI 0. 82~1. 07,P=0. 35)差异无统计学意义,同样未提升患者生存率、客观缓解率( objective response rate, ORR)和疾病控制率(disease control rate,DCR) (P>0. 05),但降低了患者疾病进展( progressive disease,PD)发生率(OR=0. 54, 95% CI 0. 29~0. 99,P=0. 05);亚组分析显示剂量密集化疗延长老年患者(≥60岁)和FIGO分期III~IV期患者的PFS(P0. 05).结论:剂量密集化疗未改善原发上皮性卵巢癌患者PFS、OS、ORR、DCR和生存率,并增加了患者3级以上贫血、腹泻发生率,但延长老年及晚期患者PFS,降低PD发生率.“,”Objective: To systematically evaluate the efficacy and safety of paclitaxel dose-dense chemotherapy in primary epithelial ovarian cancer. Methods: Conference-related abstracts and relevant articles were searched and manually retrieved from Cochrane Library, Pubmed, Embase, Medline, CINK, VIP, Wanfang, and CBM databases. We applied the Cochrane bias risk assessment tool (version 5. 1) to evaluate the risk of bias, and meta-analysis was conducted by RevMan 5. 3 software. Results: A total of 11 randomized control trials (4,590 patients) were included. Meta-analysis showed that there was no statistically significant difference between the ex-periment group and the control group in progression free survival (PFS) (HR=0. 89,95% CI 0. 77~1. 04,P=0. 14) and overall survival (OS) (HR=0. 94,95% CI 0. 82~1. 07,P=0. 35). Patient survival rate, objective response rate ( ORR) and disease control rate (DCR) were not improved (P>0. 05), while the incidence of progressive disease (PD) reduced (OR=0. 54 95% CI 0. 29~0. 99,P=0. 05). Subgroup analysis showed that dose-dense chemotherapy prolonged PFS in elderly patients (≥60 years) and FIGO stage III-IV patients (P0. 05). Conclusion: Dose-dense chemotherapy does not improve PFS, OS, ORR, DCR and survival rate in patients with primary epithelial ovarian cancer, and may increase incidence of anemia, diarrhea above grade 3. However, it may prolong PFS in elderly and advanced patients, and reduce the incidence of PD.